Marker Therapeutics, Inc. (MRKR) provided a recent update regarding its APOLLO study, which focuses on the evaluation of MT-601 in patients experiencing relapsed lymphoma. The findings reveal that 78% of the participants achieved objective response rates, with 44.4% experiencing a complete response. Additionally, MT-601 was well-tolerated, with no instances of immune-effector cell-associated neurotoxicity syndrome noted.
In conjunction with this update, Marker announced plans to sell approximately 5.03 million shares at a price of $3.20 per share, aiming to generate $16.1 million through a private placement. The proceeds from this initiative are intended to support the Phase 1 APOLLO study.
At present, Marker's stock is trading on the Nasdaq at $3.96, reflecting a decrease of 1.63%.
The material has been provided by InstaForex Company - www.instaforex.com
In conjunction with this update, Marker announced plans to sell approximately 5.03 million shares at a price of $3.20 per share, aiming to generate $16.1 million through a private placement. The proceeds from this initiative are intended to support the Phase 1 APOLLO study.
At present, Marker's stock is trading on the Nasdaq at $3.96, reflecting a decrease of 1.63%.
The material has been provided by InstaForex Company - www.instaforex.com